Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death

J Control Release. 2021 Sep 10:337:505-520. doi: 10.1016/j.jconrel.2021.07.038. Epub 2021 Jul 24.

Abstract

Low immunogenicity and immunosuppressive tumor microenvironments are major hurdles in the application of cancer immunotherapy. To date, several immunogenic cell death (ICD) inducers have been reported to boost cancer immunotherapy by triggering ICD. ICD is characterized by the release of proinflammatory cytokines, danger-associated molecular patterns (DAMPs) and tumor associated antigens which will generate anticancer immunity by triggering adaptive immune cells. However, application of ICD inducers is limited due to severe toxicity issues and inefficient localization in the tumor microenvironment. To circumvent these challenges, stimuli-responsive nanoparticles have been exploited for improving cancer immunotherapy by limiting its toxicity. The combination of stimuli-responsive nanoparticles with an ICD inducer serves as a promising strategy for increasing the clinical applications of ICD induction in cancer immunotherapy. Here, we outline recent advances in ICD mediated by stimuli-responsive nanoparticles that may be near-infrared (NIR)-responsive, pH-responsive, redox responsive, pH and enzyme responsive, or pH and redox responsive, and evaluate their significant potential for successful clinical translation in cancer immunotherapy.

Keywords: Cytokines; DAMPs; ICD; Immunogenicity; Stimuli-responsive nanomedicine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Immunogenic Cell Death
  • Immunotherapy
  • Neoplasms* / drug therapy
  • Tumor Microenvironment

Substances

  • Antineoplastic Agents